Three Ways FDA Can Lift 'Barriers' to MDx Development

The FDA should develop "consistent and clear regulatory pathways" for regulatory submissions; provide universal standard references; and establish a biorepository of rare specimens.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.